Revvity, Inc.

RVTY

$129.73

-0.69%

N/A-$0.90

Healthcare

Medical - Diagnostics & Research

NYSE

Active Trading

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of ...

CEO Profile of RVTY

Prahlad Singh

Revvity, Inc.

Age 59Tenure 7yKey-man risk: Medium

Prahlad Singh is a science-credentialed healthcare executive with long strategy/M&A leadership background, now in his CEO role since Dec 2019. Public evidence in this round supports ongoing margin focus, active...

Key Risk

•Segment/regional headwinds such as immunodiagnostics challenges in China (acknowledged by Singh, per captured 2025 snippet).

Key Tailwind

•Shareholder-return policy supported by disclosed buybacks (over $800 million repurchased in 2025, per referenced transcript snippet) and dividends ($0.07/share declared...

Prahlad Singh

Revvity, Inc. (RVTY) · NYSE

IndiaAge 59Tenure 7 yearsNon-founder CEOKey-man risk: Medium

Bachelor's degree in chemistry from the University of Bombay; PhD in chemistry; MBA (Northeastern University, Graduate School of Business Administration).

singhprahlad

youtube

Origin Story

Prahlad Singh, a chemistry-trained executive, rose through healthcare industry leadership roles (GE and Philips Healthcare) to become President and CEO of Revvity effective December 30, 2019.

Early Life: Born and raised in India; holds a bachelor's degree in chemistry from the University of Bombay and later completed advanced scientific training (PhD in chemistry).

First Break: Early career impact in major healthcare and life-sciences companies is not fully detailed in the sourced materials, but his later senior roles at GE Healthcare and Philips Healthcare are cited as foundational to his executive ascent.

Path to CEO: Revvity’s leadership materials describe Singh as having more than 25 years of leadership experience across global healthcare companies. Governance materials state he was elected President and Chief Executive Officer effective December 30, 2019 and appointed to the board in August 2019. Prior to CEO responsibilities, Revvity notes his senior executive experience in strategy, business development, and mergers and acquisitions roles spanning GE Healthcare and Philips Healthcare, including a General Manager role in GE Healthcare’s Women’s Health business. This combination of scientific grounding and large-company commercial/strategy/M&A leadership is repeatedly reflected as the basis for his CEO appointment.

Prahlad Singh’s trajectory blends deep scientific education with long-form executive experience in global healthcare. Revvity’s leadership and governance materials emphasize that he was elected President and CEO effective December 30, 2019 and appointed to the board in August 2019. They also describe his prior senior leadership exposure across GE Healthcare and Philips Healthcare, including strategy, business development, and M&A responsibilities, as well as General Manager leadership within GE Healthcare’s Women’s Health business. The public information available in this round does not provide a detailed narrative of personal early career pivots, but the consistent theme is that his technical training and cross-functional leadership prepared him to manage Revvity’s science-forward portfolio and execution expectations.

scientific operatorhealthcare executivem&a experience

Investment Take

Key Tailwinds

Shareholder-return policy supported by disclosed buybacks (over $800 million repurchased in 2025, per referenced transcript snippet) and dividends ($0.07/share declared in 2025).

Modest topline growth signals based on reported annual revenue trends (e.g., 2025 revenue +3.67% vs 2024, and 2026 twelve months ending March 31, 2026 revenue +4.79% YoY per Macrotrends snippet).

Portfolio strategy emphasis on Revvity Signals software capabilities via ACD/Labs expansion.

Key Risks

Segment/regional headwinds such as immunodiagnostics challenges in China (acknowledged by Singh, per captured 2025 snippet).

Execution risk in translating software/Signals capability expansion (e.g., ACD/Labs acquisition) into measurable financial outcomes.

Data transparency risk: several governance, R&D intensity, and CEO-attributed talent/retention metrics were not fully substantiated in captured Round 1 sources.

Career History

Singh advanced through senior strategy/business development and M&A leadership in global healthcare (GE and Philips Healthcare) before being appointed CEO of Revvity in late 2019.

Revvity, Inc. (formerly PerkinElmer)

Initiative: President and Chief Executive Officer

Period: 2019–present

Event: Elected President and CEO effective December 30, 2019; hosts earnings calls as CEO (e.g., April 28, 2025; May 5, 2026) and leads company strategy as stated in governance/leadership pages.

GE Healthcare

Initiative: Senior executive leadership (including General Manager role for Women’s Health) and strategy/business development/M&A responsibilities

Event: Described by Revvity as a General Manager for GE Healthcare’s Women’s Health business and as holding senior executive roles in strategy, business development, and M&A.

Philips Healthcare

Initiative: Senior executive leadership (strategy, business development, and M&A)

Event: Revvity describes senior executive-level roles spanning strategy, business development and M&A at Philips Healthcare.

long tenurege philips backgroundm&a

Company Performance

Under Singh, Revvity has delivered modest topline growth in recent annual metrics while maintaining profitability signals around double-digit margins in disclosed periods, alongside ongoing portfolio and margin focus in earnings materials.

Revenue: Macrotrends is cited in results for annual revenue of $2.755B (2024, +0.16% vs. 2023) and $2.856B (2025, +3.67% vs. 2024); a 2026 revenue metric for the twelve months ending March 31, 2026 is shown as $2.902B (+4.79% YoY).

Profitability: A press release cited in results reports GAAP operating profit margin from continuing operations for 2025 at 12.5% (vs 12.6% in 2024). For Q1 2026, a result reports GAAP operating profit margin from continuing operations at 10.7% (vs 10.9% in the same period a year ago).

Stock: Insufficient public data available for price change since tenure start within the sourced results captured in Round 1.

•GAAP operating profit margin from continuing operations reported at 12.5% for full-year 2025 (vs 12.6% in 2024).

•Annual revenue growth reported by Macrotrends for 2025 vs 2024 (+3.67%).

•CEO-led earnings calls hosted across 2025–2026 (e.g., April 28, 2025; May 5, 2026).

•Q1 2026 GAAP operating profit margin slightly below prior-year quarter (10.7% vs 10.9%).

•Insufficient public data available for segment/product underperformance attributable specifically to Singh beyond referenced earnings commentary.

margin focusmodest growth

Management Ability

Singh’s approach appears to emphasize disciplined executive leadership, recurring investor communication, and portfolio/margin management as evidenced by repeated earnings-call leadership and publicly described strategy responsibilities.

Style: operator with strategy/M&A orientation

Revvity’s governance and leadership pages consistently position Singh as President and CEO with election/appointment details tied to board governance. Across 2025–2026, he is repeatedly cited as the CEO hosting earnings calls, indicating an ongoing cadence of direct oversight of financial performance communication. Revvity also publicly describes leadership roles connected to strategy and M&A priorities (e.g., a Chief Digital & Strategy Officer with responsibility for strategy and M&A priorities), supporting the view that Singh’s management model is structured around defined strategy functions. Public information in this round does not provide enough detail to assess day-to-day operational execution discipline or specific org redesigns under his tenure.

investor cadencestrategy orientation

Capital Allocation

Revvity’s disclosed capital allocation includes shareholder returns (quarterly dividends) and a scale of share repurchases cited in earnings materials, suggesting active balance-sheet and per-share management under Singh.

Revvity’s board declared a regular quarterly dividend of $0.07 per share (example dates in results: July 24, 2025; Oct 23, 2025). A Q4 2025 earnings conference call transcript (cited in results) states repurchased over $800 million worth of shares in 2025 and reduced share count by 8.5% with ~28% overall reduction (as quoted in the search snippet). Profitability signals cited include 2025 GAAP operating profit margin from continuing operations of 12.5%.

Acquisition of ACD/Labs (to expand Revvity Signals software capabilities): ongoing/strategic expansion; results snippet indicates the deal was to expand breadth/depth of Revvity Signals solutions.

Public results in this round show Revvity running a shareholder return program with quarterly dividends ($0.07/share declared in 2025) and an aggressive buyback pace (over $800 million repurchased in 2025, per a referenced Q4 2025 earnings transcript snippet). The company’s capital allocation approach appears geared toward per-share value creation alongside continued investment/portfolio strategy, as reflected by a disclosed software-oriented acquisition (ACD/Labs) intended to deepen Revvity Signals capabilities. Profitability disclosures show relatively stable double-digit GAAP operating profit margins in 2025 (12.5% cited). In this round, specific ROIC/cost-of-capital outcomes tied directly to Singh’s decisions are not quantified in the captured sources.

buybacksdividendssoftware acquisition

Fundraising & Financing

No specific equity or debt fundraising amounts were confirmed in the captured Round 1 sources for Singh’s financing track record.

In this round, the sources focus on dividends and share repurchases rather than new equity issuances or major debt fundraising tied to Singh. A referenced Q4 2025 transcript snippet indicates large-scale share repurchases (over $800 million repurchased in 2025), which tends to be anti-dilutive in the short term, but dilution specifics are not computed. A dividend is disclosed ($0.07/share declared). Without captured sources on issuances, credit facilities, bond activity, or investor-proceed transaction details in the same round, a financing philosophy assessment and dilution assessment cannot be substantiated beyond buybacks/dividends.

buybacks over issuance

Governance & Control

Revvity’s governance materials confirm Singh’s CEO role and board appointment history, but dual-class control details and ownership percentages were not evidenced in the captured results.

Revvity’s governance page snippet confirms Singh was elected CEO effective December 30, 2019 and appointed to the board in August 2019. This indicates meaningful governance involvement as both CEO and director, aligning executive leadership with board oversight. However, the Round 1 captured sources do not provide dual-class structure or voting rights per share class. The results also include some general dual-class references but not company-specific evidence for Revvity, so the minority shareholder alignment/control dynamics cannot be reliably described from captured data.

board involvement

Health & Succession

No public health concerns were surfaced in captured Round 1 sources; succession readiness details beyond the initial CEO succession plan announcement are not evidenced here.

Health Status: no public concerns

Key-man Risk: Medium

A 2019 press release about leadership succession plan exists in the search results list (PerkinElmer announces leadership succession plan appointing Singh as CEO effective December 30, 2019), but current (2026) succession plan disclosure and any health/condition information were not captured in the Round 1 evidence.

health unknownsuccession not evidenced

R&D & Tech Vision

The available evidence in this round supports an innovation-and-data orientation at Revvity (e.g., Signals software expansion and leadership positioning), but specific R&D investment intensity and outcomes attributable to Singh are not quantified here.

Insufficient public data available for R&D spend as % of revenue/absolute figures in the captured Round 1 sources.

Revvity Signals software capability expansion via acquisition of ACD/Labs: ongoing with context

•Signals software capabilities expansion via ACD/Labs (announced as expanding breadth/depth of solutions bridging analytical data to action).

Revvity’s leadership narrative and a referenced acquisition announcement indicate a strategic emphasis on bridging analytical data to actionable workflows through Revvity Signals software. The ACD/Labs acquisition is explicitly described as expanding Signals’ software capabilities, which suggests a product-roadmap focus on software-driven workflow enablement in life sciences/diagnostics. Additionally, earnings-call transcript snippets in this round highlight corporate focus on margins and organic growth but do not provide enough detail to tie to an R&D portfolio outcome framework. Quantified R&D intensity, the maturity of technology platforms, or specific technical bets beyond the ACD/Labs/Signals initiative are not sufficiently evidenced in Round 1.

signals softwareinnovation narrative

Talent Recruitment

The captured sources confirm finance leadership changes and list senior executives, but they do not provide enough CEO-attributed hiring outcomes or retention/attrition metrics to grade recruitment effectiveness.

Max Krakowiak appointed Chief Financial Officer (Aug 17, 2022, per Revvity finance leadership transition news): Revvity announced finance leadership transition with Krakowiak replacing prior CFO (Jamey Mock).

Insufficient public data available for a CEO-attributed bench-strength assessment.

Revvity’s leadership materials list Singh as CEO and describe the broader leadership ecosystem (including finance leadership). A specific finance leadership transition is referenced (Max Krakowiak appointed CFO in 2022), which can indicate managerial bench-building under Singh’s CEO tenure. However, the Round 1 captured data does not enumerate multiple executive hires attributable to Singh across other functions, nor does it provide retention/attrition outcomes or employee satisfaction signals with executive-level linkage. As a result, talent recruitment effectiveness cannot be assessed beyond confirming at least one senior leadership appointment.

executive bench

Strengths

Singh’s most defensible strength from the sourced materials is his combination of scientific education and senior healthcare leadership experience (including strategy and M&A) applied at the CEO level.

strategic & M&A-informed leadership: Revvity describes prior senior roles in strategy, business development, and M&A at GE Healthcare and Philips Healthcare; under his CEO tenure, Revvity pursued expansion of Revvity Signals capabilities via the announced ACD/Labs acquisition.

consistent investor communication cadence: Investor relations materials repeatedly show Singh hosting earnings calls across 2025–2026 (e.g., April 28, 2025 and May 5, 2026).

capital returns via buybacks/dividends: A referenced Q4 2025 transcript snippet states Revvity repurchased over $800 million worth of shares in 2025, and the board declared a $0.07 quarterly dividend (examples in 2025).

m&a orientationinvestor cadencecapital returns

Weaknesses & Failures

Publicly available evidence in this round points to operational challenges in at least one geography/segment (immunodiagnostics in China), but does not establish a repeat failure pattern attributable specifically to Singh’s decisions.

regional/segment headwinds

Immunodiagnostics challenges in China were acknowledged by the CEO, indicating vulnerability to regulatory/market shifts affecting performance.

Example: A 2025 news snippet references Singh acknowledging challenges in Revvity’s immunodiagnostics business in China due to changes in regulations.

insufficient quantified linkage of CEO actions to outcomes

Key areas investors typically evaluate (R&D intensity, margin drivers by segment, executive turnover, and governance control structures like dual-class/voting rights) are not fully substantiated in the captured Round 1 sources.

segment headwindsdata gaps

Marketing & Brand

Marketing effectiveness is evidenced primarily through Revvity’s rebrand narrative (from PerkinElmer to Revvity) and recurring company positioning statements rather than quantified customer growth in the sourced round.

Revvity publicly positions itself as a science-based solutions company powering innovation from discovery to cure after the 2023 launch/rebrand messaging.

Revvity’s public newsroom/press materials describe the company launch/rebrand as a science-based solutions company leveraging innovation across life sciences and diagnostics. In this round, the results do not provide measurable marketing KPIs (e.g., lead generation, customer retention, or pricing improvements) attributable to Singh’s specific marketing strategy. However, public appearances and positioning language in earnings-adjacent sources suggest consistent messaging around innovation and human potential. More detailed evidence (e.g., investor day initiatives or specific go-to-market changes under Singh) was not captured in Round 1.

rebrandpositioning

PR & Communication

Singh demonstrates a recurring public communication posture via scheduled earnings calls and mainstream business media exposure, with limited controversy-specific detail available in this round.

Media Reputation: mixed

Event: Immunodiagnostics business challenges in China (regulatory/market changes)

Handling: Singh publicly acknowledged challenges to the immunodiagnostics business in China and discussed the drivers (per a referenced 2025 news snippet).

Revvity’s investor relations materials show Singh frequently hosting earnings calls (e.g., April 28, 2025; October 27, 2025; May 5, 2026). Results also include references to mainstream media coverage (e.g., Reuters company page snippet indicating Singh spoke during interviews around forecast outcomes). The captured results include at least one business-critical acknowledgment (immunodiagnostics challenges in China) where Singh is described as acknowledging challenges and drivers. In this round, there is not enough sourced detail to assess earnings-call clarity quality, how he handled prior crisis events beyond the single example, or the overall tone across multiple stakeholder audiences.

earnings communicationmedia presence

Supply Chain of RVTY

Upstream / Downstream / Proxies

Upstream

Thermo Fisher Scientific Inc.NYSE:TMOMerck KGaAETR:MRKAgilent Technologies Inc.NYSE:A Danaher CorporationNYSE:DHR Waters CorporationNYSE:WAT Bruker CorporationNASDAQ:BRKR Corning IncorporatedNYSE:GLWSartorius AGETR:SRT3Repligen CorporationNASDAQ:RGENCloud Software Group, Inc. (formerly TIBCO Software)

Downstream

Eli Lilly and CompanyNYSE:LLY Pfizer Inc.NYSE:PFE Novartis AGNYSE:NVS Merck & Co., Inc.NYSE:MRK Roche Holding AGOTC:RHHBY Johnson & JohnsonNYSE:JNJ AstraZeneca PLCNASDAQ:AZN Quest Diagnostics IncorporatedNYSE:DGX Labcorp Holdings Inc. (Laboratory Corporation of America)NYSE:LHRevvity Authorized Distributor Network (Global)HVD Life SciencesVarious Diagnostic OEM Customers

Proxies

Thermo Fisher Scientific Inc.NYSE:TMO Danaher CorporationNYSE:DHR Agilent Technologies Inc.NYSE:A Waters CorporationNYSE:WAT Bruker CorporationNASDAQ:BRKR

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer